Compare Abbott Laboratories (ABT) vs W W Grainger Inc (GWW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs W W Grainger Inc — how do they compare? Abbott Laboratories trades at $96.06 (market cap $166.94B), while W W Grainger Inc trades at $1,343.75 (market cap $64.04B). The key difference: Abbott Laboratories is far larger — about 2.6× W W Grainger Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | GWW | |
|---|---|---|
Market Cap | $166.94B | $64.04B |
Sector | Health | Technology |
52-Week High | $136.62 | $1.37K |
52-Week Low | $82.57 | $918.18 |
Enterprise Value | $193.69B | $66.13B |
Dividend Yield | 2.63% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GWW trades at $1,370.16, up 2.02% today, showing strong momentum with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $11.65, beating estimates by 14%, and raised full-year guidance. Revenue growth remains solid at 10.1% year-over-year, with operating margins expanding 110 basis points to 16.7%. Recent news highlights Grainger's 25-year partnership with the American Red Cross and multiple analyst upgrades citing momentum potential.
The outlook remains positive with analyst consensus target of $1,260 suggesting modest upside. Strong profitability metrics (48.1% ROE, 19.66% ROA) support valuation, though elevated P/E of 36.84 warrants monitoring. Key risks include industrial sector cyclicality and margin pressure from rising costs. Institutional sentiment leans cautious with 63% hold ratings despite recent earnings beat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
